Author Interviews, Technology / 16.01.2015

Moe Alsumidaie MBA MSF President & Chief Scientific Officer Annex ClinicalMedicalResearch.com Interview with: Moe Alsumidaie MBA MSF President & Chief Scientific Officer Annex Clinical   MedicalResearch: What is the background for this study? Response: SUMMARY: A real-world case study measuring the impact of Short Messaging System (SMS) or “Text Messaging” on clinical trial patient recruitment using an interactive two-way patient engagement platform by Mosio, Inc., which provides clinical research services designed to increase patient recruitment, engagement and retention, found that use of text messaging alone can be an effective means of patient engagement that results in clinical trial patient enrollment. Patient recruitment, retention and medication adherence continue to be challenges in conducting effective clinical trials. While clinical trials often rely on email recruitment, recent studies suggest that only 22% of emails are read.1 Alternatively, 98% of text messages are read1 and 90% of text messages are read within the first three minutes of receipt.2 Recent research has evaluated the impact of Short Messaging System (SMS) or “Text Messaging” in healthcare settings, such as appointment reminders and medication adherence. Results have demonstrated that SMS intervention significantly improved patient behavioral outcomes: patients who received SMS reminders were more likely to show up to appointments on time,3 and patients who received SMS reminders were more adherent to medications.4 However, only limited research is available on the effect of SMS on clinical trial subject enrollment. Johnson County Clin-Trials (JCCT), a clinical research facility that specializes in executing 10-15 vaccine clinical trials per year, was facing issues with enrolling patients rapidly in a tight time frame using email. To access a more effective strategy to better engage patients, JCCT employed two-way SMS/text messaging solutions, and this study assessed the impact of SMS/text messaging on patient recruitment and enrollment. (more…)
Author Interviews, Infections / 27.10.2014

Dr. Simon Corrie PhD The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, Delivery of Drugs and Genes Group Australian Infectious Diseases Research Centre, St. Lucia, Queensland, AustraliaMedicalResearch.com: Interview with: Dr. Simon Corrie PhD The University of Queensland, Australian Institute for Bioengineering and Nanotechnology, Delivery of Drugs and Genes Group Australian Infectious Diseases Research Centre, St. Lucia, Queensland, Australia Medical Research: What is the background for this study? What are the main findings? Dr. Corrie: P. falciparum malaria is a major cause of morbidity and mortality around the world, particularly in developing countries. Some estimates also suggest that in developing countries, children under 5 account for ~90% mortality. As malaria is treatable, positive detection is important rule out other causes, avoid over-treatment leading to resistance, and to guide appropriate treatment. Our focus is on developing diagnostic devices for infectious diseases, which do not require needles, lancets or laboratory processing. These devices are “microprojection arrays”, silicon chips that can be applied to the skin to capture circulating protein biomarkers in the interstitial fluid of the skin. In this publication we: (a) developed methods to improve the sensitivity of the devices for capturing HRP2, (b) confirmed that HRP2 protein injected intravenously is detectable in skin fluid and (c) showed that we could capture both HRP2 and total IgG (as a positive control for penetration into skin) at the same time. (more…)